Grant: CIHR Fellowship
McGill University
$90,000.00
Electrophysiological Measures of Proteinopathy in Asymptomatic Older Adults
EF 2023-24
Résumé
Alzheimer's disease is a progressive brain disorder that impairs memory and thinking skills and causes brain areas to shrink and brain cells to die. In Canada, there are an estimated 368,200 Canadians living with Alzheimer's disease, and this number is expected to triple in the next 30 years. The current procedure for diagnosing Alzheimer's disease involves a PET scan, where doctors measure the build-up of proteins in the brain to give an indicator of the progression of the disease. This is a reliable tool but has some drawbacks. In particular, PET is expensive, uses radiation that can be harmful to the patient if used repeatedly, and does not provide a direct measure of brain activity. For those reasons, we are interested in testing a different tool, called MEG, that can measure brain activity directly, and does not cause any harm to the patient. We want to see if the data we get from the MEG scan can accurately predict the results of the PET scan. If it can, that would mean that MEG could be used as a safe and informative alternative to PET. Our study will use data from 124 participants from the PREVENT-AD dataset. This dataset contains both MEG and PET data from healthy older adults who are risk of developing Alzheimer's disease. We will extract features of interest from the MEG data and use them to try to predict the protein levels measured by the PET scan. We will use a type of artificial intelligence called machine learning to make our predictions. The successful prediction of protein levels using MEG will help us understand how Alzheimer's disease affects brain activity and may provide a safer alternative for the diagnosis of Alzheimer's disease in the future.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
493310
Name
Power Lindsey N
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Electrophysiological Measures of Proteinopathy in Asymptomatic Older Adults
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Alzheimer'S Disease; Machine Learning; Magnetoencephalography; Neuropathology; Positron Emission Tomography; Protein Concentrations; Software; Spectral Analysis
Abstract
Alzheimer's disease is a progressive brain disorder that impairs memory and thinking skills and causes brain areas to shrink and brain cells to die. In Canada, there are an estimated 368,200 Canadians living with Alzheimer's disease, and this number is expected to triple in the next 30 years. The current procedure for diagnosing Alzheimer's disease involves a PET scan, where doctors measure the build-up of proteins in the brain to give an indicator of the progression of the disease. This is a reliable tool but has some drawbacks. In particular, PET is expensive, uses radiation that can be harmful to the patient if used repeatedly, and does not provide a direct measure of brain activity. For those reasons, we are interested in testing a different tool, called MEG, that can measure brain activity directly, and does not cause any harm to the patient. We want to see if the data we get from the MEG scan can accurately predict the results of the PET scan. If it can, that would mean that MEG could be used as a safe and informative alternative to PET. Our study will use data from 124 participants from the PREVENT-AD dataset. This dataset contains both MEG and PET data from healthy older adults who are risk of developing Alzheimer's disease. We will extract features of interest from the MEG data and use them to try to predict the protein levels measured by the PET scan. We will use a type of artificial intelligence called machine learning to make our predictions. The successful prediction of protein levels using MEG will help us understand how Alzheimer's disease affects brain activity and may provide a safer alternative for the diagnosis of Alzheimer's disease in the future.
Competitiondate
202310
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Power, Lindsey N
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~